Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Doug Bean who wrote (1547)	12/18/1999 4:46:00 PM
From: Doug Bean	Respond to of 1837

jeez,, sometime I should proof read my messages :-) Sorry , i just type and hit enter :_0 CRDoug

To: Doug Bean who wrote (1547)	12/20/1999 9:57:00 AM
From: art slott	Read Replies (1) \| Respond to of 1837

One less long suffering horse Doug. Premarin is obscene.

To: Doug Bean who wrote (1547)	12/21/1999 2:53:00 PM
From: Firenze	Read Replies (1) \| Respond to of 1837

Doug, The formulary issue is a very big deal. If Apri and Cenestin are on the formularies then plan members would be able to purchase the products at a copayment instead of the full price. However, more insurers are moving to what is called a three-tier benefit plan where the third-tier is the highest copayment. Since both are usually less than $25 per Rx then most women in these plans will not be hit that bad in the pocket, as their out-of-pocket expense will be below their copayment Firenze